INHIBITION OF THE NT-3:TRKC BOUND AND ITS APPLICATION TO THE TREATMENT OF CANCER SUCH AS NEUROBLASTOMA
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jul 3, 2014
app pub date -
Dec 19, 2013
filing date -
May 21, 2008
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The subject matter of the present disclosure relates to an in vitro method for the screening of anti-cancer compounds based on the capacity for these compounds to interact with neurotrophin 3 (NT-3 or NT3), to the extracellular domain or TrkC receptor and/or to inhibit the dimerization of the intracellular domain of the TrkC receptor expressed in tumor cells, particularly in neuroblastoma. The disclosure also relates to a method for predicting the presence of metastatic cancer or a bad prognosis cancer, or for determining the efficiency of an anti-cancer treatment based on the measuring of the expression level of neurotrophin 3. The disclosure further comprises kits and compounds as a medicament for the treatment of neuroblastoma or cancer overexpressing neurotrophin 3 by the tumor cells.
First Claim
Other Claims data not available